This month sees the launch of the ASK Real-World Evidence (RWE) programme, bringing healthcare professionals the latest emerging data on oncology biosimilars.

ASK Real-World Evidence

The ASK Real-World Evidence programme builds on the existing ASK Biosimilars programme and includes the ASK RWE abstract library conveniently broken down into 3 strategic areas - switching, implementation and economics. It provides summaries of the latest published papers, associated data, and real-world evidence concerning oncology biosimilars and includes bite-sized key takeaways.

A series of regional case studies, developed with expert regional faculty, will provide reflections on the oncology biosimilars adoption landscape for different healthcare systems including Canada, United Kingdom, Europe, Australia, America, as well as globally. Each case study will offer a localised perspective on oncology biosimilar implementation, switching and health economics for that location and will include discussion areas for consideration with patients when implementing a biosimilar switching programme.

The ASK Real-World Evidence programme’s resources will be marketed to our Oncology MDT (Multi-Disciplinary Team) community, including oncologists, hospital pharmacists, secondary care nurses, advanced practice providers, and payors, all via our media brands Hospital Pharmacy Europe and Hospital Healthcare Europe, as well as our expert faculty and worldwide societies.